Phase 3 N=28 Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
Nocturia · Daytime Sleepiness
Primary: Change From Baseline in Epworth Sleepiness Scale [ESS] — 9.03; 9.73 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=727 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Melanoma
Primary: Overall Survival (OS) — 15.70; 11.53 months — p=0.0400
Phase 3 N=60 Cryosurgery and Cream Combination for Actinic Keratosis
Actinic Keratosis
Primary: Number Participants With 100% Clearance — 12; 13 Participants
Phase 3 N=1,692 Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1) — 0.247; 0.226; 0.139; 0.165 Liters — p=<0.0001
Phase 3 N=190 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, or Discontinuation Due to AEs — 177; 38; 63; 0 participants
Phase 3 N=571 Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Actinic Keratosis
Primary: Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITT — 17.1; 78.2; 64.2 percentage of patients — p=0.0000
Phase 3 N=405 A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Unresectable or Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 27.2; 9.8 Percentage of participants
Phase 3 N=327 Pediatric Schizophrenia Efficacy and Safety Study
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6. — 94.5; 94.0; 92.8; -18.6 units on a scale — p=0.0003
Phase 3 N=49 Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
Gastric Bypass · Parathyroid Hormone
Primary: The Primary Outcome Measure With iPTH — 72; 87; 82 pg/mL
Phase 3 N=240 Effect of Self-Management on Improving Sleep Apnea Outcomes
Sleep Apnea Syndromes
Primary: CPAP Adherence — 2.8; 3.9 hours per night — p=0.001
Phase 3 N=803 Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis — -0.3; -50.2; -52.7; -1.6 percent change…
Phase 3 N=295 A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Epilepsy, Partial Seizures
Primary: Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase — 3.27; 3.19; 3.18 Seizures per 28 days
Phase 3 N=264 Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Attention-Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Visit 6 (Week 4) — 40.0; 39.0; -11.7; -21.5 Units on a scale…
Phase 3 N=363 A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score (n=102, 104, 106) — -22.85; -23.70; -24.37 Score on a scale…
Phase 3 N=402 A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A) — -0.54; 0.00 Percent — p=<0.001